Kornimate/medical-research-clean huggingface dataset:
the effect of transcranial direct current stimulation on fatigue among multiple sclerosis patients.patients

Conditions: Multiple Sclerosis

Summary: this work is aimed to assess the long term effect of tdcs in fatigue management among ms patients

multiple sclerosis (ms) is an inflammatory demyelinating disease of the central nervous system that is considered one of the most frequent causes of disability in the young adult. fatigue in ms may affect up to 80 % of the people with ms. it tends to persist over time once it appears. however, despite high frequency, fatigue remains poorly understood. fatigue in ms is neither consistently linked to disease severity nor disease duration, although it is found to be worse in individuals with the secondary progressive subtype. fatigue is distinct from sleepiness, and fails to improve with adequate sleep. multiple factors are thought to contribute to fatigue\[7 , 8\] with no specific biomarker or etiology yet confirmed. a wide variety of therapies have been tested to reduce fatigue in ms, but unfortunately, none have been consistently effective. transcranial direct current stimulation (tdcs) is a relatively recent therapeutic development that utilizes low-amplitude direct currents to induce changes in cortical excitability. although various non-invasive neuromodulation technologies are available , tdcs has unique advantages compared to other stimulation methods such as its ease of use, lower cost, and greater safety and tolerability. small preliminary studies have observed that tdcs may be a promising treatment for ms fatigue, using sham-controlled crossover designs, with five tdcs sessions, using either a motor, sensory, or dorsolateral prefrontal cortex (dlpfc). recently chalah et al.\[12\] study demonstrated that dlpfc (left anodal) when compared the posterior parietal cortex led to the most fatigue specific improvements. thus, tdcs can reduce fatigue burden for people with ms, it may be possible to implement a tdcs therapy for symptomatic management of fatigue.

Eligibility criteria:
inclusion criteria: any adult patient will be fulfilling diagnostic criteria of multiple sclerosis and could be providing consent for participation in the study, will be included in the study. exclusion criteria: * any patient showed this following condition will be excluded from the study; * any ms patient had any contraindication condition to use tms or tcds (such as epilepsy, head trauma, metallic procedure, cerebral insult) * any patient had infection or febrile condition. * any patient had other co morbid neurological or psychiatric disorders or systemic disease. * any patient refuses participation in study.

Keywords: multiple sclerosis transcranial direct current stimulation fatigue
enhancing safe sleep practices of urban low-income mothers

Conditions: Sudden Infant Death Syndrome

Summary: the specific aims of the study are to: 1) evaluate the impact of the safe sleep intervention on parents' knowledge, beliefs, intentions, skills and practices related to creating and maintaining a safe sleep environment for their infants during the first four months of life; 2) describe the characteristics of physician anticipatory guidance about safe sleep and identify physician, patient and parent characteristics associated with coverage of the topic at the well-child visits; and 3) evaluate the dissemination of the b'more for healthy babies (bhb)'s safe sleep campaign messages and services among our study participants.

this intervention trial uses a randomized controlled design and will be conducted in the harriet lane clinic. the study conditions are: standard care group (sg), attention-matched control group that receives a scald burn prevention intervention (cg), and intervention group that receives a safe sleep intervention (ig). parents or legal guardians will be enrolled during the newborn visit (when the baby is approximately 4-7 days old). while waiting to be seen for their 2-week well-child visit, the parent will complete the baseline interview and be randomized to sg, ig, or cg. all participants will receive standard of care during all of their well-child visits, which will include standard anticipatory guidance delivered by the pediatric resident. the ig and cg interventions will be delivered in the clinic during the 2-week visit after the baseline survey has been completed. the first follow-up will be conducted at the home of the parent after completing the 2-week visit, when the baby is approximately 3-6 weeks old. the second follow-up will be conducted at the home of the parent after the 2-month well-child visit, when the child is approximately 2-4 months of age. each home visit consists of an interview covering safe sleep and scald topics, an observation of the baby's sleep environment, and testing the water temperature. the 2-week and 2-month well-child visits will be audio-recorded, and parent or legal guardians will be asked to complete a visit exit checklist.

Eligibility criteria:
inclusion criteria: * adult (18 years of age) or emancipated minor. * parent or legal guardian of the child. * child is receiving care at the harriet lane clinic. * child's primary care provider is participating in the study. * english-speaking. * lives in baltimore city or baltimore county. * not homeless or not living in a shelter or in an established transitional housing facility. exclusion criteria: * not an adult or emancipated minor. * not the parent or legal guardian of the child. * child is not receiving care at the harriet lane clinic. * child's primary care provider is not participating in the study. * non english-speaker. * does not live in baltimore city or baltimore county. * homeless or living in a shelter or other established transitional housing facility.
efficacy of enhanced recovery after surgery pathway for total mastectomy

Conditions: Mastectomy; Breast Cancer Female

Summary: retrospective analysis of pre and post-enhanced recovery after surgery for total mastectomy pathway implementation.

retrospective analysis of pre- and post-enhanced recovery after surgery for total mastectomy pathway implementation in patients at mount zion hospital. we examined perioperative opioid consumption, pain scores, post-operative nausea and vomiting, benzodiazepine use, length of stay for the time period before and after implementation of an enhanced recovery after surgery pathway for total mastectomy. pathway features included preoperative acetaminophen and gabapentin, minimizing opioids, postoperative nsaids, pecs blocks, and aggressive postoperative nausea and vomiting prophylaxis.

Eligibility criteria:
inclusion criteria: * female patients at least 18 years old undergoing total skin sparing mastectomy at university of california san francisco mount zion hospital exclusion criteria: * patients undergoing concurrent bilateral salpingo-oophorectomy, flap reconstruction

Keywords: enhanced recovery after surgery (eras) fast-track surgery pec blocks mastectomy
fecal microbiota transplantation

Conditions: Depression in Schizophrenia

Summary: the primary objective will be to evaluate effectiveness, safety and acceptability of fmt on depressive symptoms at 2 months follow-up in sz patients with resistant md.

background. major depression (md) will move into the first place of cause of the global burden of disease by 2030. conventional treatments (antidepressants) are only partly effective with frequent side effects. more specifically, md is underdiagnosed and undertreated in schizophrenia (sz) despite its high impact on prognosis and quality of life in sz patients. even when treated, 44% of the patients remain major depressed under conventional antidepressants. femadsz makes the hypothesis that this is due to the fact that the source of md relies outside the brain, in the gut microbiota. the associations between microbiota disturbances are now well demonstrated in rodent models (\>60 studies) and indirect data in humans clearly suggest that the microbiota hypothesis of md is the most promising track in psychiatry. the primary objective will be to evaluate effectiveness, safety and acceptability of fmt on depressive symptoms at 2 months follow-up in sz patients with resistant md. methods: this is a pilot, single-arm, prospective, open-label proof-of-concept trial, including sz patients with resistant md. fifteen patients will be enrolled and administered a fecal microbiota transplantation. the main outcome measure will be depressive score at 2 months, adverse events and acceptability. each patient will receive a fdg-pet scan, a routine blood draw and a metagenomic microbiota analysis before and after intervention. expected results. this pilot study will help determining the effectiveness of fmt and the neurobiologic and microbiologic mechanisms associated with response to treatment.

Eligibility criteria:
inclusion criteria: * patients aged 18 to 65 years * with the current diagnosis of shizophrenia exclusion criteria: * history of lifetime fmt * history of gut surgery
convalescent plasma for covid-19

Conditions: Blood Plasma Therapy; COVID

Summary: the purpose of this proof of concept study is to provide covid-19 convalescent plasma to patients with moderate to severe covid-19 and assess: * the titer of anti-covid-19 antibodies in the donors and in the patients before and after treatment; * the in-depth analysis of immunological parameters in the donors and in recipient before and after treatment; * the impact of plasma transfusion on the reduction of viral load and inflammation * safety and tolerability * clinical efficacy


Eligibility criteria:
inclusion criteria: * hospitalized adult patients 18 - 75 y.o. with confirmed covid-19 infection by nasopharyngeal swab; * radiologically confirmed pneumonia; * spo2 \> 92o/o and \< 96% (room air); * ongoing thromboembolic prophylaxis. exclusion criteria: * participation to another covid-19 trial; * severe covid-19 disease (spo2 \< 93o/o in room air); * severe allergic transfusion reactions or anaphylaxis in the patient history; * documented lga deficiency; * unstable heart disease with signs of circulatory overload; * malignancies or other concomitant diseases with poor short-term prognosis; * pregnancy.
syndecan-1 a surrogate marker for ibd

Conditions: Inflammatory Bowel Diseases

Summary: syndecan-1 is a protein on the surface intestinal cells. previous studies proved low levels of mucosal syndecan-1 levels on the surface of intestinal cells is patients with acute and chronic inflammation due to inflammatory bowel disease. this protein might shed from cell surface to the serum. the investigators wish to prove that elevated serum levels of syndecan-1 may be predictive of disease presence, extent and severity, that buy taking a simple blood sample from patients diagnosed with inflammatory bowel disease and comparing to normal subjects and to other markers.

one of the main hypothesis for the etiology of inflammatory bowel disease (ibd) is an inappropriate and ongoing activation of the mucosal immune system in response to the presence of normal luminal flora. this aberrant response is most likely facilitated by defects in both the barrier function and the mucosal immune system of the intestinal epithelium. syndecans are a class proteoglycans that take part in both cell adhesion and growth factor binding. of the four known syndecan core proteins, syndecan-1 (cd138) and one of the best studied of this group and is also the relevant to the this study as it is expressed on the basolateral surface of columnar epithelial cells of the colon. syndecan-1 functions as an integral membrane protein that participates in cell proliferation, cell migration and cell matrix interactions in the gi tract. evidence for a reduction of syndecan-1 expression in the regenerating epithelium that overlies inflamed tissue was reported in both acute and chronic inflammation. this protein that is lost from the inflamed mucosal membrane might shed to the serum. elevated serum levels of syndecan-1 may be predictive of disease presence and extent.

Eligibility criteria:
inclusion criteria: * informed consent * no other concurrent inflammatory disease * formal diagnosis of inflammatory bowel disease i.e crohn's disease, ulcerative colitis exclusion criteria: * pregnancy * fever at time of sample taking

Keywords: crohn's disease ulcerative colitis syndecan-1
effectiveness of personalized alternating current stimulation for treating cognitive impairment in cns demyelination patients

Conditions: Multiple Sclerosis; Electric Stimulation

Summary: background: central nervous system inflammatory demyelinating diseases often lead to significant cognitive impairment, presenting a critical challenge in patient management. objective: to evaluate the effectiveness of individualized transcranial electrical stimulation (tes) in improving cognitive function among patients with inflammatory demyelinating disorders. methods: this study will assess cognitive performance through standardized neuropsychological assessments before and after individualized a one-time tes intervention, measuring changes in cognitive domains including working memory, attention, executive function, and processing speed. anticipated results: we hypothesize that personalized transcranial electrical stimulation will demonstrate significant improvements in cognitive performance, potentially offering a non-invasive therapeutic approach for managing cognitive decline in central nervous system inflammatory demyelinating diseases. significance: this research may provide novel insights into neuromodulation strategies for cognitive rehabilitation in patients with complex neurological conditions.


Eligibility criteria:
inclusion criteria: * patients with neuromyelitis optica spectrum disorders (nmosd), multiple sclerosis (ms), and other central nervous system inflammatory demyelinating diseases that meet diagnostic criteria; * patients with sdmt scores \<55 or subjective cognitive decline; * age between 18 and 65 years, gender unrestricted; * no relapse or medication changes in the past month; * edss (expanded disability status scale) score ≤6; * right-handed, native chinese speakers with sufficient educational background to understand the test instructions; -willing to participate and have signed informed consent.- exclusion criteria: * relapse record within the past month; * medication adjustment within the past month or having undergone modified electroconvulsive therapy, transcranial magnetic stimulation, or other neuromodulation techniques; * participating in any other clinical research within 1 month prior to enrollment or currently; * presence of cochlear hearing aids, cardiac pacemakers, or implanted brain stimulation devices; * skin integrity damage at electrode placement sites, or allergy to electrode gel or adhesives; * history of epilepsy, hydrocephalus, central nervous system tumors, brain injury, or intracranial infections; * pregnant or lactating women, or those planning pregnancy in the near future; * scoring ≥3 on item 3 (suicide item) of the hdrs-17 or concurrent severe mental illness; * concurrent severe or unstable organic diseases; * unable to cooperate with treatment, follow-up, or clinical, eeg, and imaging data collection due to poor patient compliance; * other situations deemed inappropriate for study participation by the researchers.
riluzole augmentation pilot in depression (rapid) trial

Conditions: Major Depressive Disorder

Summary: the investigators are doing a research study to find out if riluzole, when taken along with a standard antidepressant (sertraline) can help people with major depression. this research study will compare riluzole + sertraline to placebo + sertraline. the investigators hypothesize that adding riluzole will lead to a better antidepressant response, in less time, then sertraline alone.

recent attention has focused on the glutamatergic system as a new, distinct target for depression treatment. riluzole (rilutek, sanofi), an oral modulator of glutamate activity with neuroprotective and anticonvulsant properties, is currently approved by the united states food and drug administration for treatment of amyotrophic lateral sclerosis (als). preliminary studies using riluzole to treat depression in humans are promising, though larger, double-blinded controlled trials are needed. overall study population: adult outpatients with a current, untreated major depressive episode. disallowed therapies include: other psychotropic medications, including antipsychotics, mood stabilizers, benzodiazepines, barbiturates, other sedative-hypnotics, chronic opiates, or additional antidepressants, psychotherapy, electroconvulsive therapy, vagal nerve stimulations therapy, transcranial magnetic stimulation therapy, or phototherapy.

Eligibility criteria:
inclusion criteria: * adults (ages 18-75) who meet dsm-iv criteria for a major depressive episode, * hamilton depression rating scale (hdrs) \>22, and * no antidepressant treatment for at least three weeks exclusion criteria: * active drug or alcohol disorder in the past 3 months * history of psychosis, history of mania or hypomania * epilepsy or history of seizures * hypothyroidism * congenital qtc prolongation * liver disease * lung disease * acute suicide or homicide risk * pregnant women, breastfeeding women, women of childbearing age not using contraception * unstable medical illness * elevated thyroid-stimulating hormone (tsh\>5.0mlu/l), or * abnormal liver function tests (alt\>50 u/l or ast\>50 u/l) * add / adhd (attention deficit hyperactivity disorder) disallowed therapies include: other psychotropic medications, including antipsychotics, mood stabilizers, benzodiazepines, barbiturates, other sedative-hypnotics, chronic opiates, or additional antidepressants, psychotherapy, electroconvulsive therapy, vagal nerve stimulations therapy, transcranial magnetic stimulation therapy, or phototherapy.

Keywords: major depression major depressive disorder depression riluzole glutamate sertraline
augmenting exposure therapy with an n-methyl-d-aspartate (nmda) agonist for panic disorder

Conditions: Panic Disorder

Summary: this study involves cognitive behavioral therapy (cbt) and a medication called d-cycloserine (dcs), which is thought to help reduce panic symptoms more effectively by interacting with n-methyl-d-aspartate (nmda) glutamate receptors, facilitating many forms of learning including the extinction of fear. participants will be randomly assigned (like flipping a coin) to receive either dcs or a placebo in addition to cbt.

this study consists of cognitive behavioral therapy (cbt) including exposure to physical sensations and feared situations, which have been demonstrated to be effective for many individuals with panic disorder. all assessments and treatment sessions are free of charge. half of the patients will be randomly assigned to receive d-cycloserine (dcs) and half wll be assigned to receive a placebo. although dcs is used in humans to treat tuberculosis, it has not been fda approved for this indication. recent research in other anxiety disorders has shown that dcs plus behavior therapy is more effective than behavior therapy alone. this treatment study had two active interventions. all patients will receive cbt and the researchers expect that everybody will improve from this treatment. however, it may be that those patients in the dcs intervention will improve somewhat more than those in the placebo intervention. the treatment will be structured with at home practice and repeated assessments. assessments are extremely important as they guide the treatment and provide the study investigators necessary information about the treatment. the treatment consists of 5 sessions (once a week) plus a one week post-treatment assessment and follow-up assessments at one month and six months.

Eligibility criteria:
inclusion criteria: * principal diagnosis of panic disorder exclusion criteria: * history of psychotic disorders or bipolar disorder * substance dependence * pregnant or breastfeeding * history of a medical condition that may increase the risks of taking the study drug

Keywords: panic disorder cognitive behavioral therapy d-cycloserine medication treatment trial placebo-controlled double-blind randomized
a retrospective study to assess the outcome after surgical reconstruction of the midfoot with the midfoot fusion bolt in patients with neuroarthropathy

Conditions: Charcot Neuroarthropathy; Diabetic Foot

Summary: the aim of this study is to investigate the clinical outcomes of surgical correction of foot deformity with the mfb in a larger group of patients with neurological impairment of the foot.


Eligibility criteria:
inclusion criteria: * age ≥ 18 at date of inclusion * previous surgical reconstruction of the midfoot with midfoot fusion bolt(s) for one of the following indications: neuroarthropathy deformity of the foot with neurological impairment - signed informed consent according to local regulation exclusion criteria: - prisoner at date of inclusion

Keywords: charcot foot charcot neuroarthropathy midfoot arthrodesis midfoot fusion
efficacy and safety of leo 43204 in the field treatment of actinic keratosis on face or chest including12-month follow-up

Conditions: Actinic Keratosis

Summary: the objective of the trial is to compare the short term efficacy of leo 43204 gel with vehicle gel in ak on face or chest when applied topically once daily for 3 consecutive days as field treatment


Eligibility criteria:
inclusion criteria: * subjects with 5 to 20 clinically typical, visible and discrete aks within a treatment area of sun-damaged skin on either the full face or a contiguous area of approximately 250 cm2 (40 in2) on the chest * subjects with minimum 3 clinically typical, visible and discrete aks within a tracking area of 50 cm2 (8 in2). the tracking area must be within the treatment area exclusion criteria: * location of the treatment area (full face or chest) within 5 cm of an incompletely healed wound or within 5 cm of a suspected bcc or scc * treatment with ingenol mebutate gel in the treatment area within the last 12 months * lesions in the treatment area that have: atypical clinical appearance (e.g. hyperthrophic, hyperkeratotic or cutaneous horns) and /or, recalcitrant disease (e.g. did not respond to cryotherapy on two previous occasions) * history or evidence of skin conditions other than the trial indication that would interfere with the evaluation of the trial medication (e.g., eczema, unstable psoriasis, xeroderma pigmentosum)
long term safety and efficacy study of prosavin in parkinson's disease

Conditions: Parkinson's Disease

Summary: the study is designed to assess the long term tolerability of prosavin and whether it is safe and efficacious in patients administered prosavin from the ps1/001/07 study .


Eligibility criteria:
inclusion criteria: * must have met all inclusion criteria for study ps1/001/07 * willing to have l-dopa dosage reduced/withdrawn at the discretion of the investigator at regular intervals to allow assessment of prosavin in the absence of concomitant antiparkinsonian medication. * affiliated with the french social security health care system (patients enrolled in france only) * signed and dated written informed consent obtained from the patient and/or the patient's legally acceptable representative, if applicable, in accordance with the local regulations * must have been treated with prosavin/sham exclusion criteria: -

Keywords: prosavin gene therapy